In the US, Golimumab (golimumab systemic) is a member of the drug class TNF alfa inhibitors and is used to treat Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis, Spondyloarthritis and Ulcerative Colitis.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Disease-modifying antirheumatic drug, DMARD
Immunoglobulin G1, anti-(human tumor necrosis factor α) (human monoclonal CNTO 148 gamma1-chain), disulfide with human monoclonal CNTO 148 kappa-chain, dimer
- Golimumabum (Latin)
- Golimumab (German)
- Golimumab (French)
- Golimumab (Spanish)
- Golimumab (OS: USAN, BAN)
- Golimumab (Genetical Recombination) (OS: JAN)
- CNTO 148 (IS: Centocor)
Baxter, Russian Federation; Centocor, United States; Janssen, Australia; Janssen, Canada; Janssen, Hong Kong; Janssen, Hungary; Janssen, Iceland; Janssen, Malaysia; Janssen, Romania; Janssen, Singapore; Janssen, Slovakia; Janssen, Thailand; Janssen, South Africa; Janssen Biologics, Austria; Janssen Biologics, Greece; Janssen Biologics, Norway; Janssen Biologics B.V., Serbia; Janssen Pharmaceutical, Japan; Janssen-Cilag, Colombia; Janssen-Cilag, Czech Republic; Janssen-Cilag, Israel; Janssen-Cilag, Poland; Janssen-Cilag, Portugal; Merck Sharp & Dohme, Bosnia & Herzegowina; Merck Sharp & Dohme, Spain; Merck Sharp & Dohme, United Kingdom; Merck Sharp & Dohme, Croatia (Hrvatska); MSD, Switzerland; MSD, Denmark; MSD, Finland; MSD, Ireland; MSD, Netherlands; MSD, Sweden; MSD Belgium, Belgium; MSD France, France; MSD Merck Sharp & Dohme, Germany; MSD Merck Sharp & Dohme, Turkey; Schering-Plough, Italy; Schering-Plough, Latvia; Centocor, Lithuania
- Simponi Aria
Janssen Biotech, United States
|BAN||British Approved Name|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.